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ARTICLE
YY1 Haploinsufficiency Causes
an Intellectual Disability Syndrome Featuring
Transcriptional and Chromatin Dysfunction
Michele Gabriele,1,29 Anneke T. Vulto-van Silfhout,2,29 Pierre-Luc Germain,1,29 Alessandro Vitriolo,1
Raman Kumar,3 Evelyn Douglas,4,5 Eric Haan,4,5 Kenjiro Kosaki,6 Toshiki Takenouchi,6 Anita Rauch,7
Katharina Steindl,7 Eirik Frengen,8 Doriana Misceo,8 Christeen Ramane J. Pedurupillay,8
Petter Stromme,9 Jill A. Rosenfeld,10 Yunru Shao,10 William J. Craigen,10 Christian P. Schaaf,10
David Rodriguez-Buritica,11 Laura Farach,11 Jennifer Friedman,12 Perla Thulin,13 Scott D. McLean,14
Kimberly M. Nugent,14 Jenny Morton,15 Jillian Nicholl,4,5 Joris Andrieux,16 Asbjørg Stray-Pedersen,17
Pascal Chambon,18 Sophie Patrier,19 Sally A. Lynch,20 Susanne Kjaergaard,21 Pernille M. Tørring,22
Charlotte Brasch-Andersen,22 Anne Ronan,23 Arie van Haeringen,24 Peter J. Anderson,25 Zo¨e Powis,26
Han G. Brunner,2 Rolph Pfundt,2 Janneke H.M. Schuurs-Hoeijmakers,2 Bregje W.M. van Bon,2
Stefan Lelieveld,2 Christian Gilissen,2 Willy M. Nillesen,2 Lisenka E.L.M. Vissers,2 Jozef Gecz,3,27
David A. Koolen,2,30 Giuseppe Testa,1,28,30,* and Bert B.A. de Vries2,30,*
Yin and yang 1 (YY1) is a well-known zinc-finger transcription factor with crucial roles in normal development and malignancy.
YY1 acts both as a repressor and as an activator of gene expression. We have identified 23 individuals with de novo mutations
or deletions of YY1 and phenotypic features that define a syndrome of cognitive impairment, behavioral alterations, intrauterine
growth restriction, feeding problems, and various congenital malformations. Our combined clinical and molecular data define
‘‘YY1 syndrome’’ as a haploinsufficiency syndrome. Through immunoprecipitation of YY1-bound chromatin from affected
individuals’ cells with antibodies recognizing both ends of the protein, we show that YY1 deletions and missense mutations lead
to a global loss of YY1 binding with a preferential retention at high-occupancy sites. Finally, we uncover a widespread loss
of H3K27 acetylation in particular on the YY1-bound enhancers, underscoring a crucial role for YY1 in enhancer regulation.
Collectively, these results define a clinical syndrome caused by haploinsufficiency of YY1 through dysregulation of key transcrip-
tional regulators.
Introduction
The first study employing trio exome sequencing for
the discovery of de novo mutations in individuals with
intellectual disability (ID)1 reported a de novo mutation
in YY1 (MIM: 600013), which was considered a prime
candidate gene for ID given its known functions. YY1
encodes yin and yang 1 (YY1), a zinc-finger transcription
factor (TF) that was originally identified to repress or
activate the adeno-associated virus (AAV) P5 promoter
in the absence or presence, respectively, of the adeno-
virus E1A oncoprotein,2 as well as repress an immuno-
globulin enhancer and activate genes encoding ribo-
somal proteins.3,4 The dual function inscribed in its
name has been extended to a large number of genes
and cell types and further articulated through an addi-
tional partitioning of YY1 activity between Polycomb-
associated and -independent functions. YY1 is in fact
the mammalian homolog of Drosophila pleiohomeotic
(pho), one of the TFs that mediate recruitment of
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Polycomb group (PcG) proteins to target genes via
Polycomb response elements (PREs). Although PREs
have remained largely elusive in mammals, with a few
exceptions,5 several observations have corroborated the
functional interaction between YY1 and PcG proteins
in selected cell types.5–8 It has become clear, however,
that a significant aspect of YY1 function is PcG indepen-
dent through direct targeting by its four zinc fingers,
which manifests mostly as positive regulation of
gene expression both in mouse embryonic stem cells
and in a variety of tumor cellular models.9,10 The key
interactors for YY1-mediated transcriptional activa-
tion include the INO80 chromatin remodeling com-
plex,9,11,12 the p300/CBP histone acetyl transferase
(HAT),13 and several other transcriptional co-activators
reviewed elsewhere.14 Recently, compound-heterozygous
and homozygous nonsense variants in YY1AP1 (MIM:
607860), a component of the INO80 chromatin remodel-
ing complex, have been reported as the cause of Grange
syndrome and a fibromuscular dysplasia-like vascular
disease.15
The direct relevance of YY1 for neuronal development
and function is suggested by several lines of convergent
evidence.16 First, YY1 turned out to be haploinsufficient
for mouse development, albeit at incomplete penetrance,
such that a significant fraction of Yy1þ/ embryos show
exencephaly, pseudoventricles, and asymmetry of the
developing brain.17 Moreover, in Schwann cells, YY1
was shown to mediate the neuregulin-dependent acti-
vation of the myelination gene expression program
centered on the TF EGR2.18 In addition, YY1 has been
shown to repress chromatin remodeler HCFC1, whose
alterations lead to neurodevelopmental disorders.19,20
Finally, the interaction with the PcG axis appears partic-
ularly relevant in light of the central role of this chro-
matin regulatory axis in neural development, as shown
by us and others through the temporally highly specific
neuronal phenotypes triggered by ablation of Polycomb
repressive complex 2 (PRC2), which catalyzes methyl-
ation on lysine 27 of histone H3 (H3K27me), or of the
demethylase JMJD3, which effects regulated H3K27me3
removal.21–25
Together, these considerations prompted us to search
for YY1 mutations in additional individuals1 in order
to establish a causal link between YY1 mutations and
ID and to characterize the impact of YY1 mutations
in terms of molecular alterations and pathogenic path-
ways. Here, we define YY1 dysfunction as a cause of ID
by describing a cohort of ten individuals with de novo
mutations in YY1 and 13 individuals with small de
novo deletions that include YY1. A causal role for YY1
is further supported by the phenotypic overlap among
individuals along with the functional equivalence of
YY1 deletions and missense mutations. The genome-
wide characterization of the molecular impact of YY1
haploinsufficiency reveals transcriptional and epigenetic
dysregulation.
Material and Methods
Identification of Individuals with Mutations and
Deletions of YY1
Upon the identification of the initial individual with a de
novo mutation in YY1 (GenBank: NM_003403.4) by exome
sequencing,1 an additional cohort of 500 individuals with unex-
plained ID was tested for mutations in YY1 by standard Sanger
sequencing approaches on DNA extracted from peripheral blood.
Primers are available upon request. DNA of the parents was tested
for assessing the de novo occurrence of the identified mutations.
In addition to the two above-mentioned individuals, the re-
maining eight individuals with de novomutations in YY1were de-
tected by exome sequencing in various cohorts of individuals with
unexplained ID (Table 1), sequenced in different centers in Tokyo
(n ¼ 500), Zurich (n ¼ 350), Oslo (n ¼ 100), Houston (n ¼ 5,500),
Gaithersburg (n ¼ 6,709), and Aliso Viejo (n ¼ 1300), leading to a
total cohort of 14,969 individuals with ID.26 Exome capture was
performed with the SureSelect Human All Exon Kit V4 or V5,
Agilent Clinical Research Exome Kit (Agilent Technologies),
IDT xGen Exome Research Panel V1.0, or VCRome 2.1 (Roche
NimbleGen).27 Sequencing was performed on a MiSeq, HiSeq
2000, or HiSeq 2500 (Illumina) or SOLID 5500XL (Life Technolo-
gies). Data annotation and analysis were performed with the
Burrows-Wheeler Aligner for read alignment.28 Variant calling
was performed with the Genome Analysis Toolkit,29 XomeDx, or
in-house developed tools as described previously.30,31
The ten individuals with de novo mutations in YY1 were de-
tected by exome sequencing in a total cohort of 14,969 individuals
with ID. We calculated the probability of observing ten de novo
mutations in YY1 in 14,469 individuals as described previously32
and corrected for the total number of tested genes (19,280, enrich-
ment Agilent V5).
Individuals with deletions that included (part of) YY1were iden-
tified from DECIPHER33 and our in-house database containing
data from over 8,000 individuals with ID. Microarray analysis
was performed with the 44K, 60K, or 400K Agilent array ’(Agilent
Technologies) or 250K NspI SNP array (Affymetrix) according to
the manufacturer’s protocol.
Detailed phenotype information of individuals with YY1muta-
tions and deletions was collected.
This study was approved by the institutional review board of the
Radboud University Medical Center (Commissie Mensgebonden
Onderzoek Regio Arnhem-Nijmegen NL36191.091.11), by the
University of Milan ethics committee, and by the Neurogenetics
Research Program and South Australian Clinical Genetics
Service of Women’s & Children’s Hospital (2361/3/2017). Written
informed consent was obtained from all individuals.
LCL Culture
Lymphoblastoid cell lines (LCLs) were cultured in RPMI 1640,
15% fetal bovine serum, 1%HEPES, 1% L-glutamine, and 1%peni-
cillin-streptomycin. All LCL samples were tested for mycoplasma.
Chromatin Immunoprecipitation and ChIP-Seq Analysis
Chromatin immunoprecipitation (ChIP) was performed as previ-
ously described34 with some modification. In brief, LCLs were
centrifuged at 150 3 g for 5 min, and an average of 150 3 106
LCLs were re-suspended in 1% formaldehyde in PBS for cross-link-
ing. To stop the cross-linking reaction, glycine was added to the
final concentration of 125 mM. Cells were re-suspended with
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Table 1. Individuals with YY1 Mutations
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8 Individual 9 Individual 10
Mutation
cDNA changea c.1138G>T c.1097T>C c.1096C>G c.1030C>T c.535A>T c.1173delT c.1174_1176del c.385delG c.1015A>C c.958C>T
Protein changeb p.Asp380Tyr p.Leu366Pro p.Leu366Val p.Gln344* p.Lys179* p.Asn391Lysfs*10 p.Lys393del p.Asp129Ilefs*127 p.Lys339Gln p.His320Tyr
Chromosome
positionc
g.100743830G>T g.100743789T>C g.100743788C>G g.100742953C>T g.100706116A>T g.100743865del g.100743869–
110743871del
g.100239629delG g.100742938A>C g.100742881C>T
Inheritance de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo
PhyloPd 6.18 5.13 2.14 6.10 0.12 1.01 4.51e 2.87 4.97 6.26
MutationTaster damaging damaging damaging NA NA NA NA NA damaging damaging
PolyPhen-2 damaging damaging damaging NA NA NA NA NA damaging damaging
Cohort size 10 500 500 350 100 5,500f 5,500f 6,709f 1,300 6,709f
Growth
Age 2 years,
9 months
15 years,
10 months
5 years, 1 month 39 years 17 years,
6 months
7 years,
10 months
1 year,
3 months
35 years 9 years,
3 months
1 year,
5 months
Gender male male female female female male male female male female
Birth weight
in g (SD)
2,010 (2.5) 2,220 (3) 2,290 (1.6) NA 2,600 (2) 2,050 (1.3) 2,409 (1.8) 3.5 3.83 3,062
Height
in cm (SD)
84 (3) 170 (1) 105.2 (0.5) 153.5 (1.5) 159 (þ0.7) 124 (0) 77.2 (0.8) 154.4 (2.5) 125.5 (1.5) 79.2 (0.8)
Weight
in kg (SD)
NA 47.5 (1.5) 12.5 (2.1) 51 (1) 65 (þ0.7) 24.6 (0) 8.6 (2.6) 52.8 (þ0.3) 23 (1.7) 9.1 (1.5)
HC in cm (SD) 48.5 (1) 57 (þ0.4) 50.5 (þ0.6) 54 (1.5) 56 (þ0.7) 52.5 (0) 47.3 (0) 52.5 (2) 50 cm (1.3) 44.8 (1.8)
Development
Motor
development
sitting at 1 year;
walking
at 2 years,
9 months
walking at
2 years
sitting at 1 year;
walking at
4 years,
8 months
mild delay walking at
15 months
walking at 3 years sitting at 1 year walking at
15 months
walking at
6.5 years
sitting at
5 months;
walking at
22 months
Speech
development
first words at
2 years
first words
at 2 years
mild delay mild delay first words at
2 years
delay, 2–3 word
phrases
first words at
13 months
delay non-verbal first words
14 months
Intellectual
disability
moderate moderate mild mild mild, learning
difficulties
mild to moderate mild (DQ 68) special
education
moderate to
severe
NA
Neurological Features
Hypotonia    þ   þ  moderate 
Behavioral
abnormality
anxiety ASD NA or NK schizoaffective
disorder
ADHD    autism 
(Continued on next page)
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
1
0
0
,
9
0
7
–
9
2
5
,
Ju
n
e
1
,
2
0
1
7
9
0
9
Table 1. Continued
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8 Individual 9 Individual 10
Sleep
disturbance
  NA or NK þ þ     
Abnormal
movement
 toe walking NA or NK tremor progressive
dystonia
waddling gait  progressive
dystonia
 
Brain MRI NA normal normal frontal gliosis,
enlarged SA
spaces
normal delayed
myelination,
cortical dysplasia,
diffuse white-
matter loss
minimal
prominence
of the right
lateral ventricle
subcortical
bifrontal
white-matter
foci
focal areas of
encephalomalacia
normal
Facial Dysmorphisms
Facial
asymmetry
þ þ þ þ   mild mild þ 
Broad
forehead
þ þ þ þ þ þ þ þ þ þ
Simple
posteriorly
rotated ears
þ þ þ þ þ þ low-set simple NA or NK protruding
Periorbital
fullness
þ/ þ þ þ þ    suborbital
fullness
þ
Downslant  þ þ þ  þ   þ 
Full nasal tip þ þ þ þ þ  þ  þ þ
Malar
flattening
þ þ þ þ  þ  þ þ þ
Indented
upper lip
þ þ þ þ   þ   
Thick
lower lip
þ þ mild þ þ þ   þ þ
Pointed
chin
þ þ þ   þ    
Other telecanthus  NA or NK epiblepharon,
high palate
NA or NK Pierre-Robin
sequence
with CP
 NA or NK micrognathia,
ptosis, sparse
eyebrows
dolichocephaly,
hypotonic
facies, frontal
upsweep
(Continued on next page)
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Table 1. Continued
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8 Individual 9 Individual 10
Miscellaneous
Extremities  patella luxations,
finger joint laxity
long fingers finger joint
laxity, Sydney
line, sandal gap
hemihypotrophy
distal left leg
laterally
deviated
halluces
 NA or NK distal
arthrogryposis

Feeding
problems
þ þ þ (G-tube until
2 years,
5 months)
 þ þ (G-tube) þ (G-tube) difficulty with
chewing and
swallowing
consistently
underweight
þ
Recurrent
infections
 þ        
Eye
abnormalities
 strabismus  strabismus hypermetropia  strabismus  mild
astigmatism
strabismus
Renal
abnormalities
HN HN, UPJ stenosis      NA NA
Cardiac
abnormalities
  NA or NK   Ebstein
anomaly
PFO, small
aorto-
pulmonary
collateral
NA or NK  
Other lacrimal duct
stenosis
extensible
skin, teeth
abnormalities
neuroblastoma none esophageal
atresia, febrile
seizures,
hypothyroidism,
unilateral breast
hypoplasia
none bilateral
cryptorchidism
hypothyroidism craniosynostosis,
GH deficiency,
lacrimal duct
hypoplasia, tooth
abnormalities
hip clicking
Abbreviations are as follows: þ, present; , absent; þ/, minor; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; CP, cleft palate; DQ, developmental quotient; GH, growth hormone; G-tube,
gastrostomy tube; HC, head circumference; HN, hydronephrosis; NA, not available; NK, not known; PFO, patent foramen ovale; SA, subarachnoid; TE, trachea-oesophageal; and UPJ, ureteropelvic junction.
aGenBank: NM_003403.4.
bGenBank: NP_003394.1.
cUCSC Genome Browser build hg19.
dPhyloP scores were calculated with UCSC track vertebrate Basewise Conservation (phyloP46wayAll, hg19).
eThis is the average score for the three deleted bases: 5.13, 5.13, and 3.27.
fIndividuals 6 and 7 were detected in the same cohort of 5,500 individuals. Individuals 8 and 10 were detected in the same cohort of 6,709 individuals.
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ChIP SDS buffer (0.5% SDS, 5 mM EDTA, 100 mM NaCl, and
50 mM Tris-HCl [pH 8.1]). Pellets were collected by centrifuging
at 400 3 g for 30 min and re-suspended in immunoprecipitation
(IP) buffer (0.5% SDS, 5 mM EDTA, 100 mM NaCl, and 50 mM
Tris-HCl [pH 8.6] and 1.5% Triton X-100) To obtain a bulk of
300 bp DNA fragments, we sonicated cells with the Branson
Digital Sonifier (Emerson Industrial Automation). Chromatin
was quantified with the Bradford Protein Assay (Bio-Rad). To
immunoprecipitate YY1, we incubated 1 mg of total proteins
with YY1 antibody (sc-1703 or sc-281, Santa-Cruz Biotechnol-
ogies). For H3K27Ac ChIP, 100 mg of protein was immunoprecipi-
tated with the antibody ab4729 (Abcam). H3K27me3 IPs were
performed with 100 mg of proteins with the antibody C36B11
(Cell Signaling Technologies). Chromatin was incubated over-
night with antibody at 4C. G-Sepharose 4B (Thermo Fisher Scien-
tific) beads were incubated with chromatin and antibody mix for
4 hr at 4C and then washed with low- and high-salt buffers (1%
Triton X-100, 0.1% SDS, 150 or 500 mM NaCl, 2 mM EDTA, and
20 mM Tris-HCl [pH 8]). De-crosslinking was performed at 65C
for 3 hr. DNA was collected with the QIAquick PCR Purification
Kit (QIAGEN). Libraries were prepared as previously described35
with adaptations for the automated system Biomek FX.
ChIP sequencing (ChIP-seq) reads were trimmed for potential
adaptor contamination with Scythe 0.981 (min 4 nucleotides)
before being aligned to the hg38 genome (UCSCGenome Browser)
with Bowtie 1.0 (-v 2 -m 1), and peaks were called by MACS 2.0.9
with default settings for YY1 and with the ‘‘broad’’ option for
H3K27ac and H3K27me3. Peaks were defined as overlapping if
they shared at least one nucleotide, and bound genes were defined
as having a peakwithin 1 kb upstreamof the transcription start site
(TSS). For each target, all nucleotides falling under a peak in at least
two IPswere thenmerged into non-overlappingwindows inwhich
reads were counted and used for quantitative analysis. In addition,
for both histone modifications, an analysis was performed specif-
ically on the regions bound by YY1 (with the addition of 500 bp
on each side) andon active enhancers. In all cases andunless other-
wise specified, the number of mapped reads was used as the library
size, and edgeR v.3.12.1 (with exact test) was used for assessing the
statistical significance of the changes at the specific windows.
Because such an analysis rests on the assumption that the read-
count distributions are globally similar, and the H3K27ac data
showed signs of a global decrease, for the analysis of this dataset,
we excluded regions called as having increasedH3K27ac in the pro-
bands because thesewere likely to be artifacts of the normalization.
RNA Extraction and Quality Assessment
RNA was extracted with the RNeasy Micro Plus Kit (QIAGEN)
according to the manufacturer’s protocol. Concentration and
RNA quality were assessed by NanoDrop (NanoDrop Technolo-
gies). Prior RNA fragmentation for RNA sequencing (RNA-seq)
library construction was assessed by the 2100 Bioanalyzer (Agilent
Technologies). Only samples with an RNA integrity number > 9
were accepted for library preparation.
RNA-Seq Analysis and Differential Expression Analysis
RNA-seq libraries were prepared according to Illumina protocols
(TruSeq Stranded Ribo-Zero depletion). Sequencing was performed
with a HiSeq 2000. We performed paired-end 50 bp sequencing
on independently cultured replicates of each line (see Table S1 for
a summary of the samples and experiments). Only one of the two
batches clustered by genotype, whereas the other showed high
levels of variability partly attributable to broad variations in EP300
and a large amount of its targets. For this reason, and because the
first batch represented the same cultures from which the IPs were
performed, we first focused on this one. However, we then used
the replicated datasets, along with the subset of HapMap LCLs, in
a meta-analysis. Because the replicate samples were not fully inde-
pendent (i.e., could not be considered additional individuals) yet
were informative of the technical, stochastic, and epigenetic vari-
ability, we then focused on the high-confidence differentially ex-
pressed genes (DEGs) that were statistically significant both in the
maindataset (withadjustedpvalue<0.05) and in themeta-analysis
(withadjustedpvalue<0.1).WeperformedRNA-seqquantification
directly from the readswith Salmon 6.1,36 whichwehave shown to
beexcellent in tracking relative geneexpressiondifferences,37 byus-
ing hg38 and the RefSeq annotation complementing the sequences
of the ERCC spike-ins and Epstein-Barr virus. All differential expres-
sion analyses were performed with DESeq2 1.10.138 with the geo-
metric normalization and the Wald test, considering only genes
that had at least 20 reads in at least four samples. The merged anal-
ysis was performed with a variable accounting for the batch (i.e.,
batch þ condition). For the association with YY1 levels, ‘‘func-
tional’’ YY1 levels were used; in other words, for the purpose of
this analysis, the YY1 RNA levels of the two missense mutations
were reduced so that their mean was comparable with that of the
deletions, in line with the western blot (Figure 1C).
Enrichment Analyses
Gene Ontology (GO) enrichment analyses were performed with
the goseq R package,39 including correction for eventual RNA-
seq transcript-length bias and exclusion of genes without annota-
tion. Categories with at least 10 but no more than 1,000 genes
were considered, and Fisher’s test was used. In the main figures,
we filtered out the parent categories with significantly enriched
offspring categories to maximize the specificity of the enrich-
ments. The unfiltered enrichments are available in Table S4.
TF target enrichment analysis based on published ChIP-seq data
was performed with the hypergeometric distribution. DNA motif
enrichment analysis was performed with Homer v.4.8.40 Unless
specified, the background used for enrichment analysis was the
set of expressed and tested genes used for testing DEGs, and all
genes were used otherwise.
Permutation Analysis on the HapMap LCLs
Using the RNA-seq profiles from the HapMap LCL collection,41,42
we performed 300 random, sex-balanced differential expression
analyses (DEAs) with three samples per group and identified a sub-
set of genes with a higher tendency to be found differentially ex-
pressed in LCL lines derived from apparently healthy individuals
(with an false-discovery rate [FDR] cutoff of <0.05 in at least 2%
of the DEAs; see Table S2 for the detailed list).
Protein Extraction and Immunoblotting
For protein extraction, RIPA buffer (150 mM NaCl, 1.0% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris [pH 8.0])
was used for lysating cells. A protease inhibitor cocktail
(Sigma) was added during extraction. Cell lysates were sonicated
with the Bioruptor Sonication System (UCD200) for three cycles
of 30 s at high power with 30 s pauses and centrifuged at
13,000 3 g for 15 min. The Bradford Protein Assay (Bio-Rad) was
adopted for protein quantification according to the manufac-
turer’s protocol. For each sample, 20–40 mg of protein extract
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Figure 1. Description of the Cohort
(A) YY1 locus, including the location of the mutations identified in this study (top) and the (smoothed) frequency of non-pathogenic
(missense) mutations in the ExAC Browser (in blue, bottom).
(B) Frontal photographs sorted by age of individuals with YY1mutations (a–j). Recurrent facial dysmorphism includes facial asymmetry,
a broad forehead, fullness of the upper eyelids, and an upper lip shaped like a Gingko leaf. Each individual or his or her parents provided
informed consent for the publication of these photographs.
(C and D) YY1 levels in affected individuals’ LCLs as measured by western blot (C; the y axis indicates the ratio to b-tubulin, normalized
on the first sample) and RNA-seq (D). In (D), each bar represents the mean across two samples for the probands and nine samples for the
control individuals; error bars indicate standard deviation.
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was loaded onto home-made 10% SDS-PAGE gels. Protein
transfer were performed with a tension of 120 V for 1 hr on nitro-
cellulose membranes and blocked in 0.2% TBS-T (50 mM Tris
[pH 7.5], 150 mM NaCl, and 0.2% Tween-20) and 5% milk pre-
pared with 0.2% TBS-T. Primary and secondary antibodies were
diluted in 5%milk and 0.2% TBS-T. Western blots were performed
with the following antibodies and detected by peroxidase-based
chemiluminescence (GE Healthcare Life Sciences): YY1 (sc-1703,
1:500; Sigma) and b-tubulin (ab6046, Abcam). Densitometry was
performed with ImageJ software.
Structural Optimization of the C-Terminal Portion of
YY1 Affected by De Novo Mutations
The 3D coordinates of the YY1 zinc domain structure were
obtained from the Protein Data Bank (PDB: 1UBD 43). Hydrogens
were added, and the structure was optimized with GROMACS
5.144 and force field Amber99-ILDN45 through 200 steepest
descent minimization steps and 300 conjugate gradient
minimization steps. The structures of probands 1–4 and 7 were
built by Modeler 9.16.46 Surface accessibility was measured with
GROMACS 5.1 with default parameters, whereby the protein
was soaked in water explicit solvent with the TIP3P model.47,48
Differences in binding energies resulting from point mutations
were measured with Autodock Vina.49
External Datasets Used
The following published ChIP-seq datasets were used:
d GEO: GSM935294 (p300 in GM12878)
d GEO: GSM935611 (CTCF in GM12878; post-filtering
q < 10 3 1010)
d GEO: GSM803391 (PAX5 in GM12878)
d GEO: GSM935583 (CoREST in GM12878; post-filtering
q < 10 3 105)
d GEO: GSM935613 (ZNF143 in GM12878; post-filtering
q < 10 3 1010)
d GEO: GSM733772 (H3K4me1 in GM12878)
d GEO: GSM1003448 (HDAC1 in K562)
d GEO: GSM1003574 (CBP in K562)
In all cases, ENCODE 2014 unified narrowPeak calls were down-
loaded and lifted over to hg38, eventually with the indicated
post-filtering.
The list of chromatin interactions from GM12878 (called by
the HiCUP Hi-C pipeline50) was downloaded from GEO: GSE63525
(file ‘‘GSE63525_GM12878_primaryþreplicate_HiCCUPS_looplist.
txt.gz’’) and lifted over to hg38. We considered a YY1 binding site
to be distally in contact with a TSS if the YY1 peak overlapped an an-
chor of the loop and the second anchor overlapped the TSS.
Finally, the RNA-seq data from the HapMap LCLs were down-
loaded from the Sequence Read Archive (study ERP000101) and
processed just like the RNA-seq data produced in the present study.
Results
Identification of Individuals with De Novo Mutations in
YY1
Upon identification of the initial person with a de novo
mutation in YY1,1 Sanger sequencing of YY1 in a cohort
of 500 individuals with unexplained ID resulted in the
identification of one additional person with a de novo
mutation in YY1: c.1097T>C (p.Leu366Pro). In addition,
different exome sequencing studies in individuals with
idiopathic ID identified eight further individuals with de
novo mutations in YY1 (Table 1). This resulted in a total
of ten individuals with de novo mutations in YY1 (Figures
1A and 1B). The Bonferroni-adjusted probability of
observing this or a greater number of de novo mutations
in YY1 in our cohort was p ¼ 2.83 106, calculated as pre-
viously described.32
The phenotype of these ten individuals consisted
of cognitive impairment ranging from borderline to mod-
erate ID. Other recurrently observed features included
various behavioral problems, intrauterine growth restric-
tion (IUGR), feeding problems, eye abnormalities, and
movement abnormalities. In addition, a variety of congen-
ital abnormalities, including esophageal atresia, cleft
palate, craniosynostosis, hydronephrosis, and Ebstein
anomaly, were observed in only one or two individuals
each (Table 1). Overlapping craniofacial dysmorphisms
included facial asymmetry with a broad forehead, fullness
of the upper eyelids, and an upper-lip indentation shaped
like a Gingko leaf (Figure 1B).
Additionally, we collected data on 13 individuals with
deletions that encompassed YY1, among other genes
(Table S3 and Figure S1). The deletions ranged in size
from 75 kb to 13 Mb, and half of these also overlapped
the UPD(14) gene cluster, hence resulting in a maternal
or paternal UPD(14) phenotype (MIM: 608149). The
phenotype of these 13 individuals overlapped the pheno-
type observed in individuals with point mutations in
YY1, including developmental delay, ID, IUGR, feeding
problems, and eye abnormalities in the majority of the in-
dividuals. Similar congenital abnormalities were observed
between the two groups, albeit in a small percentage of
individuals (Table S1).
Characterization of the YY1 Variants
Of all the de novo mutations, six led to single amino acid
changes in the zinc-finger domains of YY1 (Figure 1A):
c.958C>T (p.His320Tyr), c.1015A>C (p.Lys339Gln),
c.1097T>C (p.Leu366Pro), c.1096C>G (p.Leu366Val),
c.1138G>T (p.Asp380Tyr), and c.1174_1176del
(p.Lys393del). The affected amino acid residues are highly
conserved, and at least two different programs predicted
the introduced missense changes to damage protein func-
tion (Table 1).51,52 Two mutations, nonsense c.1030C>T
(p.Gln344*) and frameshift c.1173delT (p.Asn391Lysfs*10),
were located in the (pen)ultimate exon and, as a result,
are highly unlikely to trigger nonsense-mediated decay
(NMD). Instead, these variants are predicted to give rise to
a truncated YY1 without the last two zinc fingers. The two
remaining mutations were the early frameshift c.385delG
(p.Asp129Ilefs*127) and nonsense c.535A>T (p.Lys179*).
Importantly, none of thesemutations are present in dbSNP
139, our in-house database containing exome data of over
7,000 individuals, or the Exome Aggregation Consortium
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(ExAC) Browser. By mapping all known variation over the
primary structure of YY1, we observed that all variants
found in healthy individuals involve the unstructured
amino-terminal portion of the protein, and none of them
involve its zinc-finger domains (Figure 1A). We subse-
quently mapped the probands’ mutations over residues
295–408 of the 3D structure of YY1 (PDB: 1UBD) to gain
insight into the mechanisms of action of these variants,
which are predicted to result in loss of function (Figure 2).
In brief, c.1138G>T (p.Asp380Tyr) is expected to affect a
network of salt bridges and polar interactions that might
be important for YY1 stability and for the fourth zinc finger
to correctly bend toward DNA (Figure 2A). In addition,
because residue 380 is on the solvent-accessible surface of
the protein, the substitution of residue 380 with a tyrosine
could disrupt the hydrogen bonds with surrounding resi-
dues, thus affecting the structure of the protein and its abil-
ity to interact with cofactors. Individuals 2 and 3 have
different mutations (c.1097T>C and c.1096C>G, respec-
tively) that both affect a leucine residue (Leu366) in the
middle of the DNA recognition motif, constituting a
hydrophobic core together with Phe368 and the seventh
nucleotide of the target DNA motif (Figures 2B–2D). Thus,
a substitution of Leu366 with proline or valine is likely to
Figure 2. YY1 Variants on the 3D Structure of the Protein’s DNA Binding Domain
The 3D structure of wild-type YY1’s C-terminal zinc-finger (ZN) domain is represented as a gray surface surrounding DNA, represented in
gold. ZN coordination regions are reported in light green, and missense mutated amino acid residues are reported in violet.
(A) Residues involved in polar interactions with D380 are reported in gray sticks. Hydrogen bonds are represented as yellow dashes.
(B–D) Nucleotides interacting with residues L366 and F368 are reported in sticks. Distances between L366 (B), or its variants in individ-
uals 2 (C) and 3 (D), and the closest nucleotides are reported with yellow dashes.
(E) Putative structure of the truncated form of YY1 in proband 4 is reported through depiction of its electrostatic surface.
(F) C-terminal portion of YY1 affected by proband 6 (variant in pink). The structure of the DNA-YY1 complex is reported from two oppo-
site observation sides to highlight (1) its importance for ZN coordination in the fourth ZN and (2) its role in DNA binding.
(G) Nucleotides interacting with K339 and R342 are reported in sticks. Polar interactions are reported with yellow dashes.
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be detrimental because of the lower steric hindrance of
these two amino acids. In fact, these mutations increase
the surface-accessible area of residue Phe368 by 40%.
Individual 4 has the nonsense mutation c.1030C>T
(p.Gln344*), which generates a protein missing the third
and fourth zinc fingers (Figure 2E). Individuals 6 and
7 have mutations (c.1173delT [p.Asn391Lysfs*10] and
c.1174_1176del [p.Lys393del], respectively) that destroy
the fourth zinc finger (Figure 2A and 2F). Individual 9 is
affected by c.1015A>C (p.Lys339Gln), which disrupts
the protein’s interaction with DNA. The loss in binding
energy estimated by Autodock Vina is approximately
8.42 Kcal/mol.49 Themutation c.1015A>C (p.Lys339Gln)
induces both bending of the Arg342 sidechain (partially
preventing its interaction with a guanidine residue
that is consecutive to the nucleosidic residues interact-
ing with Leu366 and Phe368 in the YY1 binding motif)
and impairment of its interaction with the next nucleo-
tide in the sequence. Finally, we can expect c.958C>T
(p.His320Tyr) in individual 10 to cause the loss of zinc co-
ordination in the first zinc finger of the DNA binding
domain and lead to a loss of DNA binding affinity on the
resulting protein.
A Panel of LCLs for the Functional Characterization of
Different YY1 Mutations
To evaluate the functional impact of the different muta-
tions on YY1 expression, we established LCLs from
four individuals and compared them with LCLs from
healthy control individuals. Specifically, we tested
LCLs of two individuals with missense mutations (individ-
uals 1 [c.1138G>T (p.Asp380Tyr)] and 2 [c.1097T>C
(p.Leu366Pro)]), one with a nonsense mutation (individ-
ual 5 [c.535A>T (p.Lys179*)]), and one with a complete
deletion of the YY1 genomic region, including only two
other genes (SLC25A29 [MIM: 615064] and SLC25A47
[MIM: 609911]) (individual 272547). Importantly, cDNA
sequencing with and without cycloheximide treatment
(Figure S2) indicated that the transcripts harboring themu-
tation causing a premature termination codon (individual
5) undergo NMD. This means that our panel effectively in-
cludes two missense mutations and two mutations leading
to loss of protein levels from one YY1 allele. We confirmed
YY1 mRNA expression and protein levels by RNA-seq
and western blot (Figures 1C and 1D), which showed
wild-type YY1 levels in LCLs from individuals 1 and 2
and 50% reduced levels in cells from individuals 5 and
272547. Thus, these findings allowed us to compare the
molecular consequences of YY1 heterozygosity with
respect to specific heterozygous missense mutations in
the zinc-finger domains.
High-Resolution Profiling of YY1 Genome-wide
Occupancy
To assess the impact of the different genetic lesions on
YY1’s DNA-binding activity, we performed ChIP-seq in
LCLs from control and affected individuals by using two
different antibodies that recognize the N- and C-terminal
regions of YY1. The two antibodies showed excellent agree-
ment, including high overlap of the peak calling (Figure 3A
and Figure S3) and a high Pearson correlation of fold en-
richments over input in the union of enriched regions
(>0.93). YY1 peaks showed a strong bias toward proximal
promoters, such that over 77% of the peaks were less
than 1 kb upstream of a TSS (Figure 3B). DNAmotif enrich-
ment analysis of these regions revealed two significant mo-
tifs that could be identified in a sizeable proportion of the
peaks: a major one very similar to the canonical YY1 bind-
ing motif (MA0095.2) was identified in >50% of the peaks
(p < 1 3 103106; 10-fold enrichment over background;
Figure 3C), and aminor one similar to the ETS bindingmo-
tifs, especially FLI1, was identified in >20% of the peaks
(2-fold enrichment over background; Figure S4B). Virtu-
ally all YY1 bindings at promoters were co-occupied by
ZNF143, and more than half of YY1-bound sites were
shared among CoREST, PAX5, CTCF, and either HDAC1
or CBP (Figure S4A). The YY1-bound genes were enriched
with genes regulating transcription, translation, and
mRNA processing (Figure 3D and Table S4).
Missense Mutations and YY1 Hemizygosity Both Lead to
a Global Loss of YY1 Binding
The LCL samples of the four affected individuals tested
showed a marked decrease in the number of YY1 peaks,
which was not accounted for by differences in coverage
(p  4 3 104 by analysis of variance). Of note, the peaks
that were lost or retained were consistent across samples
irrespectively of genetic lesion (i.e., missense mutations,
truncatingmutations, or deletions), thus underscoring hap-
loinsufficiency as the core mechanism underlying this con-
dition. The high-occupancy peaks (defined by either high
read density or high enrichment over the input)wereprefer-
entially retained (Figure 3A), as expected. ‘‘Lost’’ YY1 peaks,
i.e., peaks found in at least seven of ten IPs from the control
samples and in none of the probands (416 peaks), showed a
similar prevalence of themajorYY1DNA-bindingmotif and
were still enriched with promoter regions, but considerably
less so than high-occupancy peaks detected (Figure 3B).
Although one proband sample showed a higher number
of peaks than the other probands, this was mainly due to
its higher coverage, which disappeared upon quantitative
analysis (below). A very small number of peaks were called
exclusively in proband IPs, particularly in the c.1138G>T
(p.Asp380Tyr) sample. Although these regions did not
have genome-wide significance in the control samples,
all of them showed an enrichment over the input in
most control samples (Figure S5). Moreover, the number
of gained regions was smaller than the mean or median
number of regions unique to any control sample, which
strongly suggests that they were due to background genetic
variability rather than to a gain of function of the mutant
p.Asp380Tyr protein.
Because peak calling is coverage and threshold sensi-
tive and because conserved peaks might still show
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Figure 3. ChIP-Seq for YY1 in LCLs Derived from Affected Individuals
(A) Overlap between the peaks detected in each sample and each antibody. Each horizontal line represents a peak, shown in white if it
was undetected in a sample, in light brown if it was detected in only one of the two IPs, and in dark brown if it was detected with both
antibodies. Above are shown the sex of each LCL line, the YY1mRNA expression and protein levels, and the coverage of the correspond-
ing ChIP-seq experiments. TPM stands for transcripts per million, and FC stands for fold change in relation to the control samples. In red
on the left are shown the average log-transformed read density and log enrichment for each peak.
(B) Distribution of conserved and ‘‘lost’’ YY1 peaks across genomic features.
(C) Dominant YY1 DNA-binding motif identified.
(D) Top most-specific Gene Ontology (GO) enrichments of the YY1 target genes.
(E) Principal-component analysis of the log-transformed enrichments over the input across the union of YY1-enriched regions.
(F) YY1 enrichment over input across the different IPs (columns) and enriched regions (rows).
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Figure 4. Transcriptional Impact of the YY1 Mutation
(A) Principal-component analysis of the RNA-seq dataset.
(B) Volcano plot of the differentially expressed genes (DEGs) highlights YY1-bound genes.
(C) Expression of YY1-bound DEGs (left), along with the detected YY1 peaks at their TSS (right).
(legend continued on next page)
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quantitative differences in binding, we corroborated these
results by looking at the read distribution over peaks.
Independently of the normalization procedure, the IPs
clearly clustered by genetic condition (Figure 3E), con-
firming the clear-cut impact of YY1 dosage on its
genome-wide occupancy (Figure 3F and Figures S6–S8).
Indeed, when the read distributions were linearly normal-
ized on the total library size, proband samples showed a
considerable decrease in the proportion of reads mapping
to all YY1 binding sites (p < 0.00016, Mann-Whitney test;
95% confidence interval between 43% and 87%; see
Figure S6). Because linear normalization of ChIP-seq
data can be problematic,53 we confirmed this global
decrease by using two additional normalization methods
based on very different assumptions, both of which
gave milder but statistically significant decreases in global
YY1 binding (Figure S7). Differential-binding analysis
based on library-size normalization showed a significant,
95% decrease in YY1-bound regions. We also confirmed,
on the basis of read counts, the bias toward the conserva-
tion of highly enriched sites (Figure 3F and Figure S8),
indicating that the facility of peak calling at those sites
was not the only reason for their preferential retention
upon the decrease in effective YY1 levels. We next inves-
tigated whether peaks more or less sensitive to YY1 dosage
were associated with specific co-bindings. Compared with
the 1,000 peaks showing the greatest reduction in the pro-
bands, the 1,000 YY1 peaks showing the lowest reduction
were particularly enriched with bindings of cofactors such
as CoREST (p  2 3 108), p300 (p  3 3 107), PAX5
(p  5 3 1010), and HDAC1 (p  3 3 1014, Chi-square
test; see also Figure S9). In contrast, no significant differ-
ence was observed for bindings of CTCF and ZNF143, sug-
gesting that YY1 binding is dependent on only a subset of
its cofactors.
Finally, we did not detect any significant difference in
the read distributions between the LCLs of individuals
with YY1 deletions and those of individuals with missense
mutations (excluding regions on chromosomes X and Y
because of sex differences). This finding excludes that the
missense mutations studied lead to aberrant recruitment
of the protein to novel targets and support our hypothesis
that the different mutations all lead to haploinsufficiency
of YY1 function. As with every disorder caused by
missense mutations, it remains possible that they could
also contribute to phenotypic expressivity or variability
through gains of function (not associated with DNA bind-
ing in this specific case).
YY1 Haploinsufficiency Leads to Differential Expression
of Only a Minority of Its Targets
To assess the extent to which the observed reduction in
YY1 binding results in transcriptional dysregulation of
the target genes, we performed RNA-seq on the same set
of LCL samples plus an additional control sample. YY1-
associated changes did not dominate transcriptional vari-
ability, but the samples clustered by genotype according
to the second principal component (Figure 4A). The first
principal component correlated with no known biological
or technical factor (sex, age, coverage, sequencing lane,
RNA extraction efficiency, or proportion of ribosomal or
Epstein-Barr virus RNA). Gene-set enrichment analysis on
the whole expressed transcriptome revealed positive en-
richments in several curated gene sets related to the cell cy-
cle, transcription, and genomemaintenance (Table S5).We
identified 152 DEGs between proband and control LCLs
(Figure 4B and Table S6), which were significantly enriched
with genes related to chromatin silencing (p  9 3 1010),
aligning with the enrichment of chromatin remodelers
among genes associated with autism spectrum disorder.54
The DEGs bound by YY1, along with the peaks detected
in each sample, are shown in Figure 4C. Despite the
massive decrease in YY1 DNA binding, only a minority
(<1%) of YY1-bound genes turned out to be differentially
expressed (and only 21% of the DEGs were bound by YY1).
To improve the robustness of this analysis, we included
transcriptomes from independently cultured replicates of
the same samples and leveraged a panel of 73 transcrip-
tional profiles from the HapMap collection of LCLs derived
from apparently healthy individuals.42 We performed a
large number of permutation analyses to identify genes
often differentially expressed between healthy individuals
(see Figures S10A and S10B and Material and Methods).55
Importantly, the HapMap dataset revealed important vari-
ations in chromatin regulators, including YY1 itself, as well
as some of its key partners, such as EP300 and CREBBP,
which explained a large proportion of the transcriptomic
variance (Figure S8C). Although broad variation suggests
that LCLs might not be the ideal cell type for studying
these pathways, it also offers an opportunity to detect
associated expression patterns. We therefore harnessed
this variability to identify a large set of genes (6,687) that
were significantly associated with YY1 levels (see Material
and Methods) and that significantly overlapped YY1-
bound genes (Figure 4E; see Figure 4D for the GO enrich-
ments of the intersection). Finally, we performed a
meta-analysis of the two RNA-seq datasets in this study
(D) Top most-specific GO enrichments of the YY1-bound genes that show a significant association with YY1 mRNA levels across
HapMap LCLs.
(E) Overlap between the DEGs and YY1-bound and YY1-associated genes.
(F) Top most-specific GO enrichments of all DEGs.
(G) Expression of high-confidence DEGs (consistently dysregulated in the meta-analysis with the HapMap LCLs), along with eventual
YY1 bindings at their TSS.
In (C) and (G), expression is shown as Z scores of log-transformed normalized counts, and YY1 binding is indicated in light brown if it
was detected in only one of the two IPs and in dark brown if it was detected with both antibodies.
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(18 samples) and an equally sized subset of the HapMap
LCLs by selecting the samples that had YY1 levels compa-
rable with those of our control samples (see Material and
Methods). On this basis, we identified both a lenient set
of candidate DEGs (Table S6), whose GO enrichments are
shown in Figure 4F, and a set of 50 high-confidence
DEGs significant in both analyses (Figure 4G).
This analysis further corroborated the identified dysregu-
lations and also confirmed the relatively small overlap
with differential YY1 binding. On average, DEGs had a
greater decrease in YY1 binding than genes not detected
as having a statistically significant difference in expression
(p 13 104), although the large overlap between the two
distributions (see Figure S11A) suggests that other factors,
such as the presence of binding partners, is likely to distin-
guish YY1-dosage-dependent, transcriptionally affected
genes in any given cellular state. We therefore looked for
enrichment among the DEGs for predicted targets of
known TFs. After excluding very low (<2) enrichment
scores, the only significant enrichment identified was
for predicted targets of FLI1 (p  1 3 1010, 13% of the
DEGs and <3% of the expressed genes) on the basis of
the MA0149.1 motif. It is interesting that, as mentioned
earlier, a very similar motif was found to be enriched in
the sequence surrounding the summit of YY1 peaks. How-
ever, neither FLI1 nor any of its known interactors were
differentially expressed in the probands. In addition, on
the basis of the published ChIP-seq data on related cell
types, we detected a significant enrichment among DEGs
for targets of ATF2 (p  2 3 1097, 28% of the DEGs)
and ATF3 (p  6 3 1026, 20% of the DEGs). Of note,
YY1 binds the TSS of both TFs, and although neither of
them was detected as statistically significant in the differ-
ential expression analysis, ATF2 showed a significant
correlation with YY1mRNA levels across the whole cohort
of LCLs from the meta-analysis (p  8 3 1013; see
Figure S11B). The DEGs were also enriched with targets
of CEBPB (1.9-fold, FDR  0.001), CHD1 (1.5-fold, FDR
 0.002), and EZH2 (1.9-fold, FDR  0.002), all of which
showed statistically significant correlation with YY1 levels
in the HapMap LCLs, pointing to potential mediators of
the effects of YY1 haploinsufficiency.
YY1 Haploinsufficiency Is Associated with Widespread
Loss of H3K27 Acetylation
YY1 forms complexes with several important histone ace-
tylases and de-acetylases, including HDAC1, HDAC2,
p300, and CBP, whose antagonistic functions account at
least in part for the bivalent role of YY1 in transcriptional
repression and activation. Because most DEGs in YY1 pro-
bands were downregulated, we focused on the impact of
YY1 haploinsufficiency on histone acetyltransferases by
performing ChIP-seq for H3K27ac, selected as a marker of
both active promoters and enhancers and hence allowing
interrogation of both kinds of regulatory regions targeted
by YY1. Consistently, we found that H3K27ac distribution
clustered proband samples apart from control samples
(Figure 5A and Figures S12A and S12B), confirming the hy-
pothesis that the effect of the mutation is at least mostly
mediated by the regulation of this modification. Linear
normalization on library size suggested a global reduction
of H3K27ac in the proband samples (Figures S12C and
S12D), although the difference did not stand out with
alternative normalization methods (Figure S13), and even
though the difference in the number of peaks was statisti-
cally significant (p  0.012), it was relatively small in
magnitude (10% fewer peaks). We therefore proceeded
with the most conservative analysis, namely focusing on
sites that were showing reduced H3K27ac even under the
assumption of no difference in the global distribution
(see Material and Methods). Although this analysis poten-
tially underestimates the regions losing H3K27ac, it
excludes the possibility that spurious regions will be iden-
tified as artifacts of normalization. Even with this most
stringent method, 39% of the YY1-bound DEGs lost
H3K27ac at their proximal promoter. Of note, however,
99% of the regions showing reduced H3K27ac in probands
were on active enhancers (defined by enrichment in
H3K4me1 and H3K27ac), the majority of which were not
proximal to the TSS, suggesting an important component
of distal regulation. Indeed, although the majority of YY1
bindings were located at the TSS (Figure 3B), these results
were consistent with the involvement of YY1 in chromatin
looping56,57 and prompted us to test the possibility that
YY1 binding at distal enhancers might have a stronger
impact on gene expression. Indeed, of the YY1 binding
sites that were not in the proximal promoter of a gene,
65% were on active enhancers, whereas fewer than 4%
were on poised enhancers (defined by enrichment in
H3K4me1 and H3K27me3). Proband samples showed a
marked decreased in H3K27ac of YY1-bound active
enhancers (Figures 5B and 5C and Figure S14) that was
independent of read counts and normalization method
(Figures S15A and S15B), and the fold changes in YY1
and H3K27ac enrichments at active enhancers were posi-
tively correlated (p < 2.2 3 1016), further corroborating
that the deacetylation was dependent on YY1 haploinsuf-
ficiency. Furthermore, after normalization on library size,
82% of YY1-bound enhancers showed a statistically signif-
icant decrease in H3K27ac, in contrast with merely 25% of
the other active enhancers. However, only 15% of the
enhancers overlapping the 500 YY1 peaks least affected
by dosage showed a reduction in H3K27ac, underscoring
a crucial cis role for YY1 in regulating enhancer activation.
We therefore used the kilobase-pair-resolution Hi-C pro-
files of GM12878 LCLs58 to identify chromatin loops
that would link distal regulatory sites to the TSS of putative
target genes. We identified 545 genes that were distally
bound by YY1 (Figures S16 and S17), of which 206 were
also bound at the TSS. Although only a minority of these
were differentially expressed, genes distally bound by
YY1 were significantly enriched with DEGs (p  6 3 108
with respect to the whole genome and p  7 3 104
with respect to the expressed genes, hypergeometric test).
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Compared with genes proximally bound by YY1, distally
bound genes were much more likely to be differentially
expressed (p  1.5 3 105, chi-square test), indicating
that despite its preferential enrichment at the TSS, YY1 af-
fects its distal targets disproportionately more.
YY1 Haploinsufficiency Leads to a Switch from
Acetylation to Methylation
Loss of acetylation leaves the H3K27 substrate available for
PRC2-mediated methylation, which is associated with
repression. To investigate whether the YY1-dependent
changes in H3K27ac were followed by Polycomb marking,
we profiled H3K27me3 on the same set of samples.
Although we observed no difference in the global amount
of H3K27me3 between control and proband samples, the
loss of H3K27ac was associated with an increase in
H3K27me3 (p < 2 3 1016; see Figure S18) across YY1-
bound regions, particularly those enriched with H3K27ac
and H3K27me3 in any sample. Although only a minority
of these regions showed a statistically significant difference
after correction for multiple testing, including cap binding
complex dependent translation initiation factor (CTIF
[MIM: 613178]), the increase in H3K27me3 is likely to
underlie the predominant downregulation of DEGs in pro-
band samples.
Discussion
We characterized pathogenic mutations in YY1 in ten indi-
viduals with overlapping phenotypes, whose molecular
dissection defines a neurodevelopmental syndrome. His-
torically, YY1 was proposed as a candidate ID-associated
gene in our original trio sequencing in 2010.1 Our com-
bined clinical data indeed confirm ID as the core feature
of the syndrome, which also includes variable expression
of other comorbidities such as IUGR, feeding problems,
behavioral problems, craniofacial dysmorphisms, and
congenital anomalies. In addition, we showed relevant
phenotypic overlaps with 13 more cases of deletions
encompassing YY1. With the inherent limitations due
to sample size and the phenotypic variability of a new
Figure 5. YY1 Haploinsufficiency Results in Enhancer Dysregulation
(A) Principal-component analysis of the H3K27ac read-count distribution across all enriched regions segregates proband from control
samples (probands in red and controls in blue).
(B) Distribution of H3K27ac read densities at YY1-bound enhancers shows a marked reduction in probands. RPKM stands for reads per
kilobase pair per million reads mapped.
(C) Preferential loss of H3K27ac at YY1-bound versus non-YY1-bound enhancers. The p value is the result of a two-tailed t-test.
(D–F) Schematic representation of our key findings: YY1 haploinsufficiency and variants in the zinc-finger domain both result in a global
loss of YY1 binding (D), associated with loss of H3K27ac (E); only a minority of differentially bound genes are differentially expressed,
and the proportion is significantly higher for distal YY1 bindings (F).
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syndrome, we observed nomajor differences between phe-
notypes associated with point mutations and those arising
from deletions of YY1. Given that many of the deletions
are large and encompass multiple genes, the phenotypic
features in these persons might not be definitely attributed
to YY1. As an example, half of the deletions also encom-
passed the UPD(14) gene cluster, whose rearrangements
result in a maternal or paternal UPD(14) phenotype.59,60
Because the majority of individuals with maternal
UPD(14) have IUGR, the occurrence of this phenotype,
for example, could be related to the YY1 deletion, to the
deletion of the UPD(14) gene cluster, or to their combina-
tion. Interestingly, however, maternal UPD(14) is generally
not associated with ID, so the concurrent deletion of YY1
could explain the ID that is observed in individuals with
UPD(14)mat phenotypes. In order to further delineate
the clinical spectrum associated with de novo mutations
in YY1, we established a website to collect detailed clinical
information on additional individuals who will be identi-
fied over the coming years (see Web Resources).
The overlapping phenotype of individuals with
missense mutations, protein-truncating mutations, and
deletions of YY1 indicates loss of function as the underly-
ing mechanism. Importantly, neither YY1 loss-of-function
mutations nor missense variations in YY1 zinc-finger do-
mains have been identified in the ExAC Browser. Instead,
all missense mutations in the probands map to zinc fin-
gers, highlighting the pathogenic relevance of YY1 DNA
binding. Indeed, our analyses of LCLs from control and
affected individuals show that the missense mutations
alter YY1 DNA binding as much as truncating mutations
or deletions (as captured by two distinct antibodies
recognizing each end of the protein), pointing to YY1 hap-
loinsufficiency as the core pathogenic mechanism under-
lying this syndrome. This is also supported by the growth
and neurological alterations in the Yy-1 heterozygous
knockout mice17 and further corroborated by the observa-
tion that the phenotype of Yy-1 knockdown inmice is also
dosage dependent.61
Our key findings on the molecular impact of the muta-
tions are summarized in Figures 5D–5F. YY1 haploinsuffi-
ciency, regardless of whether it is due to deletions or
missense mutations, leads to massive loss of genome-
wide YY1 occupancy. The impact is larger on lower-occu-
pancy YY1 binding sites and is accompanied by major
changes in histone acetylation, in line with known interac-
tions between YY1 and several histone acetyltransferases
and deacetylases.62 Furthermore, our results show the spe-
cific loss of H3K27Ac at YY1-bound enhancers, indepen-
dent of signal-to-noise ratio and normalization method,
indicating an important and heretofore neglected role of
YY1 in enhancer regulation and in line with recent evi-
dence on enhancers as a key site of dysregulation for
several ID syndromes, several of which are being reframed
as enhanceropathies.62
Importantly, the targets differentially bound by YY1
include a number of genes causally involved in neurodeve-
lopmental disorders and autism spectrum disorders, such
as (1) GTF2I (MIM: 601679), encoding a TF of the genetic
interval hemi-deleted or duplicated in, respectively, Wil-
liams-Beuren syndrome (MIM: 194050) and the reciprocal
Williams-Beuren region duplication syndrome (MIM:
609757), for which converging lines of evidence indicate
a key role in the cognitive-behavioral phenotypes of
the two conditions;63–66 (2) KANSL1 (MIM: 612452),
whose deletion causes Koolen-de Vries syndrome (MIM:
610443), also involving ID;67,68 (3) NRXN2 (MIM:
600566), which has been causally associated with
autism69 and further corroborated by a recent mouse
model;70,71 (4)MED12 (MIM: 300188), mutations in which
causes syndromic forms of ID; (5) NSD1 (MIM: 606681)
mutations in which cause Sotos syndrome (MIM:
117550); and (6) ZBTB20, associated with Primrose syn-
drome (MIM: 259050), which encompasses ID and sys-
temic abnormalities.72–76
Importantly, only a minority of the genes losing YY1
binding showed significant differential expression in
LCLs, including additional genes already implicated in
neurodevelopmental disorders, such as RNASEH2C (MIM:
610329) and NBEA (MIM: 604889).77 Thus, although the
proportion of transcriptionally sensitive targets increased
as YY1 binding decreased and was greater for enhancers
than for TSS bindings, the overall delta between YY1-
dosage-dependent occupancy changes and transcription
suggest that although YY1 shows low rewiring78 and
high conservation of binding sites across tissues, its tran-
scriptional impact is highly cell-type specific and is most
likely mediated by its co-factors. This offers a plausible
explanation for the phenotypic variability of individuals,
given that background genetic variation influencing the
expression or binding of co-factors, which could be buff-
ered in the context of normal YY1 dosage, could instead
become clinically penetrant upon halving of YY1 dosage.
Moreover, only a minority of the TSSs losing YY1 binding
showed significant differential expression, an observation
that might explain the comparatively moderate clinical
phenotype for a transcription factor that has such a central
role as YY1.
In conclusion, we have shown that both deletions and
de novo point mutations affecting YY1 function cause a
haploinsufficiency syndrome of ID with a broad range of
growth and behavioral comorbidities.
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